Zhang Fangyuan, Yu Dandan, Yang Jinru, Zhai Menglan, Li Lisha, Zhao Lei, Wang Jing, Zhang Tao, Lin Zhenyu
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China.
Oncol Lett. 2023 Jun 7;26(1):319. doi: 10.3892/ol.2023.13905. eCollection 2023 Jul.
The present study was aimed at looking for hematological indicators that could predict pathological complete response (pCR) in patients with locally advanced rectal cancer (LARC) treated with short-course radiotherapy (SCRT) followed by chemotherapy and immunotherapy. A total of 171 patients were enrolled in this observational retrospective study. Pretreatment values of albumin, total cholesterol, lactate dehydrogenase, neutrophil, platelet and lymphocytes were available. Univariate and multivariate logistics analyses were used to determine the prognostic factor for pCR. SCRT followed by chemotherapy and immunotherapy was demonstrated to double the pCR rate (50.5%) compared with long-course chemoradiotherapy. For the former group, baseline high platelet to lymphocyte ratio (P=0.047), high cholesterol (P=0.026) and low neutrophils (P=0.012) level were associated with high pCR rate and baseline high cholesterol (P=0.016) and low neutrophils (P=0.020) level were the independent prognostic factors for pCR. In conclusion, pretreatment high cholesterol and low neutrophils were the independent prognostic predictors of pCR in patients with LARC treated with SCRT followed by chemotherapy and immunotherapy. Clinical trial no. NCT04928807, June 16, 2021.
本研究旨在寻找血液学指标,以预测接受短程放疗(SCRT)后序贯化疗和免疫治疗的局部晚期直肠癌(LARC)患者的病理完全缓解(pCR)情况。共有171例患者纳入了这项观察性回顾性研究。可获取白蛋白、总胆固醇、乳酸脱氢酶、中性粒细胞、血小板和淋巴细胞的治疗前数值。采用单因素和多因素逻辑回归分析来确定pCR的预后因素。与长程放化疗相比,SCRT后序贯化疗和免疫治疗使pCR率翻倍(50.5%)。对于前一组,基线高血小板与淋巴细胞比值(P = 0.047)、高胆固醇(P = 0.026)和低中性粒细胞水平(P = 0.012)与高pCR率相关,且基线高胆固醇(P = 0.016)和低中性粒细胞水平(P = 0.020)是pCR的独立预后因素。总之,在接受SCRT后序贯化疗和免疫治疗的LARC患者中,治疗前高胆固醇和低中性粒细胞是pCR的独立预后预测指标。临床试验编号:NCT04928807,2021年6月16日。